Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Medicine for treating infectious diarrhea and peptic ulcer, preparing method and applications thereof

A technology for peptic ulcer and infectious diarrhea, applied in the digestive system, drug combination, medical formula, etc., can solve the problem of not neutralizing gastric acid, etc., achieve strong effect, do not cause renal insufficiency, and do not damage visual function

Inactive Publication Date: 2008-07-30
蔡忠彬
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the prior art, rifaximin unilateral preparations, such as rifaximin tablets, commonly used in the treatment of causes, can only kill intestinal pathogenic bacteria, fail to neutralize gastric acid, astringe and protect the intestinal mucosa, and prevent excessive dehydration of the body, Functions such as intestinal mucosa shedding, electrolyte disturbance and nutritional deficiency

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating infectious diarrhea and peptic ulcer, preparing method and applications thereof
  • Medicine for treating infectious diarrhea and peptic ulcer, preparing method and applications thereof
  • Medicine for treating infectious diarrhea and peptic ulcer, preparing method and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0091] Rifaximin 100g, bismuth subnitrate 300g, starch 20g, hypromellose 17g, magnesium stearate 2.5g.

[0092] According to the conventional preparation method, the above-mentioned raw materials are crushed and mixed uniformly, granulated with 3% hypromellose as a binder, dried, granulated, and encapsulated to obtain a capsule, which is made into 1000 capsules; it can also be compressed The tablets are made into tablets; or packed into granules; or the raw and auxiliary materials are directly mixed, bagged, and made into powders.

Embodiment 2

[0094] Rifaximin 50g, bismuth subnitrate 150g, starch 10g, hypromellose 17g, magnesium stearate 2.5g.

[0095] According to the conventional preparation method, the above-mentioned raw materials are pulverized and mixed uniformly, granulated with 3% hypromellose as a binder, dried, granulated, and encapsulated to obtain a capsule, which is made into 1000 capsules; it can also be compressed Tablets are made into tablets; or packaged into granules; or raw and auxiliary materials are directly mixed, bagged, and made into powders.

Embodiment 3

[0097] Rifaximin 100g, bismuth subcarbonate 600g, starch 10g, low-substituted hydroxypropyl cellulose 15g, hypromellose 17g, magnesium stearate 2.5g.

[0098] According to the conventional preparation method, the above-mentioned raw materials are pulverized and mixed uniformly, granulated with 3% hypromellose as a binder, dried, granulated, and encapsulated to obtain a capsule, which is made into 1000 capsules; it can also be compressed Tablets are made into tablets; or packaged into granules; or raw and auxiliary materials are directly mixed, bagged, and made into powders.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention which provides a drug curing infectious diarrhea and peptic ulcer comprises the effective components of 1 to 48 percent of rifaximin and 52 to 99 percent of convergent protective agent. The drug of the invention can prevent the synthesis of bacteria RNA, kill the bacteria RNA and can also neutralize the gastric acid to avoid the abscission of gastrointestinal mucosa caused by the infectious diarrhea so as to protect the gastrointestinal mucosa and accelerate the body rehabilitation. The invention improves the efficacy, reduces the toxicity and shortens the course of treatment on the present technical base and also provides a preparation method and application of the drug of the invention.

Description

Technical field [0001] The invention relates to a medicine for treating infectious diarrhea and peptic ulcer, and a preparation method and application thereof, in particular to a compound medicine composed of an intestinal antibiotic and a chemical raw material medicine, and a preparation method and application thereof. Background technique [0002] At present, enteritis, dysentery and peptic ulcer are relatively common diseases of the digestive system. Infectious diarrhea is a common symptom of enteritis and dysentery, which seriously threatens human health. It is considered to be one of the five common symptoms and causes children under five years of age. One of the top five killers of child deaths. The impact of diarrhea on humans is mainly to restrict activities, hinder social communication, make many people unable to work normally, and seriously affect people's quality of life. Infectious diarrhea is a serious problem that people all over the world must face. Its morbidity a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/437A61K9/14A61K9/16A61K9/20A61K9/48A61K47/36A61K47/38A61P1/04A61P1/12A61P31/04
CPCY02A50/30
Inventor 蔡忠彬腾秀娟
Owner 蔡忠彬
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com